Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Veza se sprema u međuspremnik
StatusRegrutovanje
Sponzori
Danish Headache Center
Saradnici
Odense University Hospital

Ključne riječi

Sažetak

Idiopathic intracranial hypertension (IIH) is a condition of unknown etiology, primarily affecting overweight females of childbearing age. Typically, patients experience headache and visual symptoms due to increased intracranial pressure (ICP) and papilledema. The diagnosis is difficult, and outcomes vary from no sequelae to blindness or chronic headaches. No clear prognostic indicators exist. Treatment consists of medication, weight loss, and possibly surgical intervention.There is an unmet need of defining biomarkers with prognostic or diagnostic value and defining predictors of a poor outcome.
This project is a prospective, population-based cohort study including clinical data and a biobank (blood samples and cerebrospinal fluid).
The investigator's primary aim is to identify biomarkers of diagnostic or prognostic value and to create a clinical IIH database. The clinical database will answer questions about patient characteristics at baseline and during follow-up, identify predictors of outcome, and help create a standardized programme for follow-up and

Opis

This study is a multicenter, prospective, population-based cohort study with consecutive inclusion of patients in which the diagnosis of IIH is suspected. This study is carried out in collaboration between the Danish Headache Center, Rigshospitalet-Glostrup, and the Neurological Department at Odense University Hospital.

Patients are eligible for inclusion into the study if:

1. IIH is suspected

2. > 18 years old and able to provide written informed consent.

At baseline included patients will have:

A.) Medical history B.) Neurological, ophthalmological and general medical examination C.) Relevant neuro-imaging D.) Blood samples and lumbar puncture F.) Evaluation by other specialist, including neuro-psychologists, if appropriate.

Subsequently patients are divided into three sub-groups according to revised Friedmann criteria:

1. Certain IIH or IIH-WOP

2. Suspected, but unconfirmed, IIH

3. IIH ruled out

Patients are followed at a headache center and by neuro-ophthalmologist according to standard clinical practice.

Datumi

Posljednja provjera: 06/30/2019
Prvo podneseno: 07/11/2019
Predviđena prijava predata: 07/22/2019
Prvo objavljeno: 07/24/2019
Zadnje ažuriranje poslato: 07/22/2019
Posljednje ažuriranje objavljeno: 07/24/2019
Stvarni datum početka studija: 02/13/2018
Procijenjeni datum primarnog završetka: 05/30/2022
Predviđeni datum završetka studije: 05/30/2022

Stanje ili bolest

Benign Intracranial Hypertension

Intervencija / liječenje

Other: Standard treatment

Faza

-

Grupe ruku

ArmIntervencija / liječenje
Certain IIH or IIH-WOP
According to revised diagnostic criteria, Friedmann, 2013.
Suspected IIH
IIH is suspected, does not fulfill diagnostic criteria.
IIH ruled out
Patients in whom another diagnosis is made.

Kriteriji prihvatljivosti

Uzrast podoban za studiranje 18 Years To 18 Years
Polovi podobni za studiranjeAll
Metoda uzorkovanjaNon-Probability Sample
Prihvaća zdrave volontereDa
Kriterijumi

Inclusion Criteria:

1. Able to and willing to provide informed consent

2. More than 18 years of age

3. Suspicion of IIH (based on clinical evaluation by neurologist or opthalmologist)

Exclusion Criteria:

1.) Unable to consent (e.g. language, mental retardation).

Ishod

Primarne mjere ishoda

1. Biomarkers of IIH (diagnostic and prognostic) [2 years]

Analyses of CSF and blood for protein-markers (method: Proteomics)

2. Visual status at conclusion of study [2 years]

Assessment of visual fields

3. Visual status at conclusion of study [2 years]

Assessment of OCT

4. Visual status at conclusion of study [2 years]

Assessment of visual acuity

5. Headache status at conclusion of study [2 years]

Prevalence of chronic headache (>=15 headache days per month)

6. Biomarkers of IIH (diagnostic and prognostic) [2 years]

Analyses of CSF and blood for markers of metabolism (method: Metabolomics)

Sekundarne mjere ishoda

1. Baseline characteristics related to poor outcome [1 year]

Poor outcome is defined as either a.) Persistent visual field defects, decreased visual acuity after 12 months and or b.) Headache >= 15 days per month after 12 months

2. Results of neuropsychological evaluations [1 year]

Standard neuro-psychological tests

3. Treatment and follow-up [3 years]

Length and type of treatment and follow-up

4. Baseline characteristics related to IIH diagnosis [2 years]

Evaluation of disease presentation in the different sub-groups focusing on headache phenotype, visual disturbances and pulsatile tinnitus.

5. Weight change in a standard care program [2 years]

Unit of measurement is BMI

6. Diagnostic criteria and their use in the clinical setting [2 years]

Revised Friedmann criteria of 2013

7. Clinical markers related to disease activity [2 years]

Clinical markers of relevance: Headache phenotype, pulsatile tinnitus, visual disturbances, weight changes.

8. Development of IIH or IIHWOP in patients with borderline elevated ICP not fulfilling diagnostic criteria at baseline [2 years]

ICP is measured by lumbar puncture, borderline elevated ICP is considered >20-30 mmH2O

Pridružite se našoj
facebook stranici

Najkompletnija baza ljekovitog bilja potpomognuta naukom

  • Radi na 55 jezika
  • Biljni lijekovi potpomognuti naukom
  • Prepoznavanje biljaka po slici
  • Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
  • Pročitajte naučne publikacije povezane sa vašom pretragom
  • Pretražite ljekovito bilje po učincima
  • Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima

Google Play badgeApp Store badge